AACR 2023 | Can addition of novel ICIs improve PD-(L)1 blockade in NSCLC?

David Carbone, MD, PhD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, comments on the efficacy of combining alternative immune checkpoint inhibitors (ICIs) such as anti-TIGIT antibodies with existing anti-PD-(L)1 therapies in non-small cell lung cancer (NSCLC). Whilst studies have shown anti-TIGIT antibodies with atezolizumab to be a promising strategy, more research is needed to fully assess their efficacy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.